Unicycive Therapeutics, Inc. (UNCY) Misses Q1 EPS by 82c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Noble Capital Reiterates Outperform Rating on Unicycive Therapeutics (UNCY)
May 14, 2024 8:44 AM EDTNoble Capital analyst Robert LeBoyer reiterated an Outperform rating and $6.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).
The analyst comments "We Believe OLC Will Have Advantages Over Other Phosphate Binding Drugs.
OLC was formulated to reduce pill burden and improve compliance in... More
